95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studiesHINGHAM, Mass., May 03, 2023 Microbot Medical Inc. , the. | May 3, 2023
03.05.2023 - 95% success rate of reaching pre-determined vascular target with no intraoperative complications presented during pre-clinical studiesHINGHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) - Microbot Medical Inc. (Nasdaq: MBOT), the developer of the .
/PRNewswire/ Identifai-Genetics, developer of unique AI-based solutions for non-invasive fetal DNA sequencing, announced today that it has completed a.